<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemiaWei‐Ying Jen, Tapan M. Kadia, Koji Sasaki et al.|British Journal of Haematology|2025Cited by 3
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemiaNitin Jain, William G. Wierda, Alessandra Ferrajoli et al.|Blood|2025Cited by 3